JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
⁃ Patients must meet all of the following inclusion criteria to be enrolled:
• Age range: 18 to 80 years old (inclusive), both male and female are acceptable;
• ECOG: 0-2;
• B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed;
• At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment; Acceptable organ function at screening;
Locations
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Contact Information
Primary
Bang.an Peng, Master
bang.an_peng@junshipharma.com
13526844722
Time Frame
Start Date: 2025-08-17
Estimated Completion Date: 2027-04-06
Participants
Target number of participants: 180
Treatments
Experimental: DLBCL-Gemox
In participants with relapsed/refractory diffuse large B cell lymphoma ineligible for ASCT
Experimental: DLBCL-ICE
In participants with relapsed/refractory diffuse large B cell lymphoma intended for ASCT
Experimental: DLBCL- RCHOP
In participants with newly diagnosed diffuse large B cell lymphoma
Experimental: FL-Lena
In participants with relapsed/refractory follicular lymphoma
Experimental: MCL-Lena
In participants with relapsed/refractory mantle cell lymphoma
Experimental: MZL-Lena
In participants with relapsed/refractory marginal zone lymphoma
Related Therapeutic Areas
Sponsors
Leads: Shanghai Junshi Bioscience Co., Ltd.